Clinical Trial Update: PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

View source ↗

Summary

This update describes a post-authorization safety study (PASS) of Xromi evaluating safety and effectiveness in children under 2 with sickle cell disease; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• XROMI (HYDROXYUREA)

Snippet

Sponsor: Nova Laboratories Limited | Conditions: Sickle Cell Disease | Status: RECRUITING